 Adverum Biotechnologies Inc NASDAQ: ADVM announced a restructuring plan, including reductions in headcount and expenses, to prioritize its clinical development of ADVM-022, a single intravitreal injection for wet age-related macular degeneration AMD. Adverum intends these. 